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Introduction
Niemann-Pick disease type C (NPC, OMIM# 
257220) is a progressive pan-ethnic autosomal recessive 
lysosomal lipid storage disorder, with an estimated 
incidence of 1 in 100,000 live birthsworldwide [1]. It is 
characterized by impaired intracellular lipid trafficking 
leadingto the aggregation of unesterified cholesterol 
and sphingolipids in different body organs such 
as liver, spleen, and brain [2]. The disease has an 
extremely heterogeneous clinical presentation, includes 
visceral abnormalities, neurological, and psychiatric 
manifestations that appear alone or in combination 
with various ages of onset [3]. Splenomegaly with or 
without hepatomegalyand prolonged neonatal jaundice 
are common visceral manifestations. The classic 
neurological symptoms mainly include “cerebellar ataxia, 
dysarthria, dysphagia, cataplexy, and progressive 
dementia” in addition to vertical supranuclear gaze palsy 
(VSGP) which represents a major disease characteristic 
feature [4].
NPC is caused mainly by a biallelic mutation in 
either of NPC1 (95% of cases) or NPC2 (4% of cases) 
gene [5]. NPC1 is located on chromosome 18q11–12, 
contains 25 exons, and encodes a 1278 amino acid 
glycoprotein with 13 transmembrane domains [6]. Up 
till now, more than 400 various NPC1 mutations have 
been described in NPC patients, including insertions, 
deletions, duplications, nonsense, and missense 
mutations [7]. Although these mutations are scattered 
throughout the gene, the cysteine-rich luminal loop 
(amino acid residues: 857–1015) was reported as a hot 
spot regionencountering around one-third of the revealed 
mutations. While, in other literature, the putative sterol 
sensing domain was reported as a second hot spot 
region, including around 20% of revealed mutations [8]. 
In addition, the amino acid residues(1038–1253) in the 
c-terminal carboxyl end of protein were also previously 
mentionedas a hot spotfor pathogenic variants. Some 
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Abstract
BACKGROUND: Niemann-Pick disease type C (NPC) is a rare, autosomal recessive, progressive neuro-
visceraldisease caused by biallelic mutations in either NPC1gene (95% of cases) or NPC2 gene.
AIM: This caseseries study aimed at the molecular analysis of certain hot spots of NPC1 genein NPC Egyptian 
patients.
METHODS: The study included 15 unrelated NPC patients and selected parents,as well as20 healthy controls 
of matched sex and age. Clinical investigations were performed according to well established clinical criteria. 
Assessment of the chitotriosidase level, as an initial screening tool for NPC, was done in all cases. Polymerase 
chain reaction amplification of NPC1 exons (17–25) encountering the hotspot residues (855–1098 and1038–1253) 
was carried out followed by direct sequencingfor mutational analysis.
RESULTS: All includedpatients with mainly neurovisceral involvement were characterized. The onset of the disease 
varied from early-infantile (58.3%) to late-infantile (26.7%) and juvenile-onset (6.7%). Ahigh chitotriosidase level 
wasobservedin all patients. Molecular analysis of NPC1 (exons 17–25) confirmed 15 mutant alleles out of 30 studied 
ones. They included two novel homozygous missense variants (p.Ser1169Arg and p.Ser1197Phe) and previously 
reportedfour mutations (p.Arg958*, p.Gly910Ser, p.Ala927Glyfs*38, and andp.Cys1011*).
CONCLUSION: The two studied amino acid residues (855–1098 and 1038–1253) could beconsidered aspotential 
hotspot regions in NPC1 Egyptian patients.
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NPC1 mutations showed recurrent distribution globally 
or among different populations. p.Ils1061Thr is the 
most common reported mutation and widely distributed 
in Western Europe. p.Pro1007Ala is reported as the 
second most recurrent mutationin different populations, 
especially in Germany. p.Arg1186His is widely distributed 
inthe Czech, while Gly992Trp is individualized to Nova 
Scotian patients [9].
Disease-specific drugs such as miglustat can 
slow down neurological disease progression [10]. New 
therapeutic approaches such as gene therapy showed 
promising results in vitro and in vivo and it is supposed to 
be applied in the clinical stage in the near future [11]. In 
our study, we investigated certain clinical, biochemical, 
and molecular features in 15 NPC Egyptian patientsto 
contribute a better disease characterization in Egypt. 
We aimed at the characterizationof certain NPC1 
hotspot regions (residues: 855–1098 and 1038–1253), 
especially they also encounter the most common NPC1 
mutations worldwide, hopefully, to contribute in disease 
diagnosis confirmation and proper genetic counseling 
among NPC Egyptian patients.
Patients and Methods
The current caseseries study was conducted 
on 15 NPC Egyptian patients with an age range 
between 6 months and 10 years(mean ± SD, 3.2 
± 3 years)andsome selected parents as well as 20 
healthy controls with matched age and sex during the 
period from September 2017 to November 2019.
The patients were referred to the clinical 
genetics and biochemical genetics departments at 
the National Research Center (NRC), Cairo, Egypt. 
All cases were diagnosed as NPC according to their 
clinical presentation and biochemical studies. They 
were also subjected to history taking include: Age of 
patients, sex, age of disease onset, and consanguinity. 
Blood samples were obtained from patients after having 
written informed approval from their parents or their 
legal guardians. The study protocol was approved by 
the Medical Research Ethics Committee at NRC.
Clinical examinations
All included patients were clinically diagnosed, 
according to Millat et al. [12]. Abdominal ultrasonography, 
magnetic resonance imaging (MRI) of the brain, and 
electroencephalography were performed for all patients.
Biochemical studies
Peripheral leukocytic β-glucocerebrosidase 
and peripheral leukocytic acid sphingomyelinase 
enzymes were measured to exclude similar metabolic 
diseases such as Gaucher and Niemann-Pick 
Type A and Type B diseases [13], [14]. Evaluation of 
chitotriosidase biomarker as a recommended screening 
tool for NPC was done [15].
Molecular studies
DNA extraction
DNA was extracted from peripheral blood 
lymphocytes from 15 NPC patients, selected 
parents, and 20 healthy controls by salting out 
technique [16]. The DNA concentration was measured 
at a 260/280 nm absorbance ratio by NanoDrop 2000c 
Spectrophotometer (Thermo Fisher).
Polymerase chain reaction (PCR) 
amplification of NPC1 exons (17–25)
PCR was performed in a total volume of 
30 μl containing 100–200 ng genomic DNA, 30 pmol 
of each primer,230 μM of dATP, dCTP, dTTP, and 
dGTP, 2.5μM Mgcl2, 1 X Taq buffer and 2.5 U Taq 
polymerase. PCR was performed for nineexons of 
NPC1 gene. The primers sequencewas previously 
described byTarugi et al. [17], Table S1. Amplification 
of the nine exons was performed with an initial 
denaturation step at 95°C for 5 min followed by 
35cycles (each comprising 94°Cfor 40 s, 65°Cfor 
40 s, and 72°Cfor 40 s) and a final extension step 
at 72°Cfor 10 min. The reaction was carried out in 
BioRad thermal cycler. Each PCR product was 
verifiedby electrophoresis on a 1.5%(w/v) agarose 
gel and visualization by UV light.
Purification of the PCR product
PCR products were purified using EXO/SAP 
PCR Purification Kit(Thermo Fisher Scientific Baltics, 
UAB, Lithuania);2 μl EXO/SAP cocktail (4 U Exo I 
and 0.4 U SAP) were added to 6 μl PCR product. The 
mix was incubated at 37°Cfor 60 min, then at 80°Cfor 
20 min.
Direct DNA sequencing of NPC exons 
(17–25)
PCR amplified fragments were sequenced in 
both directions using primers and a BigDye Terminator 
Cycle Sequencing Kit v1.1 (Applied Biosystems, 
Warrington, UK), samples were run on an ABI 
PRISM Genetic Analyzer 3500 (Applied Biosystems). 
Sequences were compared using Basic Local Alignment 
Search Tool [18].
All variants were described according to 
nomenclature recommendation by the human genome 
variations society [19]. Sequence analysis of NPC1was 
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analyzed regarding the reference sequence of(GenBank 
accession no. NPC1, NM_000271.4).
In silico analysis
All annotated variants were examined in 
several databases, including ClinVar [20], HGMD [7], 
and gnomAD databases [21].
Functional prediction analysis, including 
PolyPhen2 [22], SIFT [23], and Mutation Taster [24], 
was used to evaluate the functional effect of novel non-
synonymous amino acid substitutions. NPC1mutation 
tolerance was further analyzed usingthe MetaDome 
webserver [25].
Prediction of protein structural effect after novel 
nonsynonymous variations was performed by Project 
HOPEto predict structural variation between native 
protein and the variant model [26]. Protein sequence 
and structure were retrieved from UniProt “Universal 
Protein Resource” [27]. The UniProt ID number of the 
aligned human sequences of NPC1: “UniProt: O15118.”
Results
Clinical data
This study included 15 Egyptian patients 
belongingto15 unrelated families. Consanguinity 
was certain in 12 families (80%). They were9 males 
(60%)and6 females (40%) and their age ranged from 
6 months to 10 years(mean ± SD, 3.2 ± 3 years). 
The onset of the disease varies from early infantile to 
juvenile form. Accordingly, our patients were classified 
into early infantile (<2 years) in 7 patients (46.7%), late 
infantile (2–5 years) in 4 patients (26.7%), and juvenile 
(5–16 years) in 1 patient (6.7%). Hepatosplenomegaly 
was the most common disease systemic feature in 
(60%) of cases, while splenomegaly restricted to 
33.3% of them. Neurological manifestations were 
obvious in 12 patients (80%), classified as early 
infantile-onset (58.3%), late infantile-onset (33.3%), 
and juvenile-onset (8.3%). Dysphagia, cataplexy, 
hypotonia, delayed developmental milestones, 
speech retardation, loss of previously acquired skills, 
ataxia, epilepsy, and vertical supranuclear gaze 
palsy VSGP were themain observable neurological 
manifestations. Brain MRI was performed in all 
patients, around (46.7%) of casesshowed cerebral 
and cortical atrophy, whilemild cortical atrophic 
changeswere observed in (33.3%), on the other hand 
around (20%)showed normal MRI. Detailed clinical 
data are illustrated in Table 1.
Biochemical studies
Assessment of peripheral leukocytic 
β-glucocerebrosidase and peripheral leukocytic acid 
sphingomyelinase enzymes showed normal values in all 
patients, while a remarkable elevation in chitotriosidase 
activitywas observed in all patients(Table S2).
Molecular studies
Molecular analysis of 9 exons of NPC1 
(exons 17–25) confirmed sixdifferent mutations. 
Two homozygous novel missense variants in the 
amino acid residues (1038–1253) were detected and 
they have already been submitted to ClinVar under 
accessions SCV001197997 and SCV001197998. The 
novel mutations were p.Ser1169Arg in the cytoplasmic 
loop L and p.Ser1197Phe in the 12th TM domain 
(Figure 1). Molecular analysis of parents showed 
heterozygous status for the novel variants, and the 20 
healthy individuals showed wild type sequences. Four 
previously reported mutations were detected in the 
cysteine-rich luminal loop classified as, one nonsense 
homozygous mutationp. Arg958*, one heterozygous 
missense mutation p.Gly910Ser, additionally, two 
homozygous frameshift mutations p.Ala927Glyfs*38, 
p.Cys1011* (Figure S1). Positions of novel revealed 
variants can be visualized in NPC1 protein topology 
produced by Protter software (Figure S2) [28].
In silico results
All revealed variants were not identified 
in the overall populations as referenced inthe 
gnomADdatabase expect p.Gly910Serand 
p.Arg958*which showed minor allele frequency 
(0.000007953)and (0.000003982), respectively. 
Both mutations were also reported as pathogenic 
variants in the ClinVar database. The novel sequence 
variations were evaluated through the alignment of 
amino acid sequences from eight different organisms 
and alterations are located within conserved residues 
suggesting an effect on proteins functions or structures 
(Figure S3). Pathogenicity of novel missense variations 
was confirmed using different web-based tools 
(PolyPhen2, SIFT, and Mutation Taster). According 
to the guidelines by the American College of Medical 
Genetics and Genomics, both of p.Ser1169Arg and 
p.Ser1197phe were found to be likely pathogenic 
variants. MetaDome web server showed that two novel 
variants are located in regions intolerant for missense 
variation. According to project HOPE, novel missense 
variantsp. Ser1169Arg and p.Ser1197Phe were 
predicted to make harmful effects on proteins binding 
and folding processes causing subsequently protein 
malfunction (Figure 2). In silico analysis, results are all 
summarized in (Table 2).
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Discussion
NPCis an autosomal recessive lysosomal 
storage diseasemainly caused by homozygous or 
compounds heterozygous mutations in NPC1 (95% of 
cases) [1]. Early disease diagnosis is very crucial for 
proper initiation of treatment and inhibition of disease 
progression [3]. In the current study, 15 Egyptian 
patients clinically and biochemically diagnosed as NPC. 
As previously mentioned, NPC exhibits broad clinical 
heterogeneity and wide presentation [29], which is 
illustrated herein. Ourpatients showed a remarkable 
phenotypic variability and their age ranged from 
Figure 1: Pedigrees and chromatograms of four families 4, 3, 7, 13. (a) Squares indicate males; circles indicate females; the black symbols 
indicate affected individuals; the half-black symbols indicate carriers, arrows indicate the molecularly studied probands. (b) Novel variants of 
NPC1 in 4 probands. The upper chromatogram in each frame represents the variant sequence, the lower one depicts the reference sequence, 
and the two middle sequences represent the parent’s heterozygous sequences
a
b
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6 months to 10 years old. Around 80% ofcases were 
diagnosed after the presence of 
neurologicalmanifestations, while the diagnosis was 
only established according to systemic signs in other 
cases (20%), systemic manifestations such as 
hepatosplenomegaly or splenomegaly were obvious in 
the majority of cases (93.3%) this is consistent with 
previous literature where systemic manifestations 
areusually present preceding to neurological onsetwith 
the exception of few percentages of 
patients(approximately,15%) [30]. The early infantile-
onset was the most common form in our study;it 
represents(46.5%) of cases followed by the late 
infantile-onset (26.7%) while the juvenile onset was 
only present in (6.7%) of cases. This agrees with the 
previous studies that reported the early infantile form as 
the most frequent disease form in Southern Europe 
(>20% of cases) and the Middle East [30]. However, a 
previous Egyptian study reported the neonatal form as 
a predominating form, followed by an early infantile 
onset of disease [31]. Remarkably, although severe 
neonatal cholestatic jaundice is more common in classic 
NPC, this feature was absent in the current study. 
Herein, the majority of pediatric patients’ manifestations 
(≤4 years) such as splenomegaly, hepatosplenomegaly, 
hypotonia, delayed neuro-psychomotor, ataxia, and 
cataplexy are in agreement with the common previously 
reported NPC signs in pediatric patients [1]. Clinical 
manifestations observed in included patients (>4 years) 
such as cognitive decline, epilepsy, and VSGP were 
more commonly described in younger NPC patients [30]. 
Denoting the biochemical analysis, high chitotriosidase 
levels were detected in all included patients, which is a 
useful initial screening tool for disease diagnosis. 
Although other previous studies showed an elevated 
level of chitotriosidase in NPC patients, other 
assessments are required for proper diagnosis, as it is 
not a specific NPC diagnostic marker [32]. Consequently, 
disease diagnosis must be finally confirmed by 
molecular analysis, which isalso considered as the only 
major tool for prenatal diagnosis, family studies, and 
carrier detection. Up till now, more than 400 disease-
causing NPC1 mutationshave been reported [33]. 
Although they are widely scattered over the geneother 
studies considered some regions such as 
residues(855–1098) in the cysteine-rich luminal loop 
and residues(1038–1253) which shares 34.7% with 
PTC1, as hot spot regions for NPC disease 
mutations[34]. In this study, molecular analysis of nine 
exons (17–25) of NPC1 encountering the previously 
suggested hot spot residues(855–1098) and (1038–
1253) revealed six different mutations (15 mutant 
alleles) in eightunrelated patients. Regarding the high 
consanguinity rate in our population, homozygous 
mutations were predominated. Patients showed 
different geographical distributions, they originatefrom 
different governorates all over Egypt. Around 23% 
(7/30) of the 30 studied alleles showed variations in the 
cysteine-rich luminal loop (residues 855–1098), while 
26.7% (8/30) of them showed alterations at the amino 
acid residues(1038–1253). Distribution of mutations in 
the two studied amino acid residues (855–1098 and 
1038–1253)was consistent with the previously 
described [34], [35]; moreover, a recent Egyptian study 
showed that around 37% of detected mutant alleles 
were in the currently studied hotspot regions [31], 
confirming that they can also be considered as hot spot 
regions in NPC Egyptian patients. Although the 
missense mutations p.Ile1061Thr, p.Arg1186His, 
p.Pro1007Ala, and Gly992Trp were previously reported 
as the most common NPC mutations [9], none of them 
were detected in the present study;however, 
p.Ile1061Thr was reported in the heterozygous state 
coupled with p.Ser627Arg in an Egyptian patient with 
the late infantile onset of disease [31]. Among severely 
affected patients, we identified one nonsense 
homozygous mutation, p.Arg958* inpatient9 led to 
protein truncation in exon 19 within the cysteine-rich 
luminal loop between TM8 and 9. The patient showed 
early infantile onset of disease, splenomegaly was the 
main systemic feature, while neurological manifestations 
such as hypotonia and delayed developmental 
milestone started to appear at the age of 6 months, the 
same mutation was also reported in a previous Egyptian 
study in two unrelated patients with neonatal and 
infantile onset of disease [31]. However, it was observed 
in the compound heterozygous state in a case with 
adult-onset of disease in a study applied in Western 
Europe and the USA [36]. This illustrates the severity of 
the mutation in the disease progression, as all the 
reported cases carryingthe homozygous p.Arg958* 
mutation was of early disease onset. However, the case 
Table 2: In silico analysis of novel revealed variants
cDNA variant 
(NM_000271.4)
Mutation effect on protein 
(NP_ 000262.1)
GnomAD PolyPhen-2 SIFT Mutation taster MetaDome tolerance ClinVar HOPE
c.3590C>T p.Ser1197Phe 0 Probably damaging Deleterious Pathogenic Slightly intolerant No entry Protein malfunction
c. 3507C>G p.Ser1169Arg 0 Probably damaging Deleterious Pathogenic Intolerant No entry Protein malfunction
Figure 2: Structural variation between native protein and the variant 
models according to hope project, (a) zoom in variantp. Ser1169Arg, 
the protein is colored gray, the side chains of the wild type (serine) and 
the mutant (Arginine) residue are colored green and red, respectively, 
(b) zoom in variant p.Ser1197Phe, the protein is colored gray; the 
side chains of the wild type (serine) and the mutant (phenylalanine) 
residue are colored green and red, respectively
a b
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previously mentioned reported by Bauer et al., [36], the 
neurological manifestations appeared in the adult stage 
due to the less severe missense mutation p.Asp874Val. 
Two frameshift mutations (c.3032_3038delins10bp 
p.Cys1011*) and (c.2779dupG p.Ala927Glyfs*38) were 
separately observed in the homozygous form in patients 
10 and 11, respectively, both mutations led to losing of 
essential domains of NPC1 protein and subsequent 
protein function impairment. Patient 10 showed a late 
infantile onset of disease and was suffering from 
hepatosplenomegaly in the early stage of life, while 
after 2 years of age, progressive neurological 
manifestations began to appear such as, dysphagia, 
cataplexy, delayed developmental milestone, 
psychomotor, speech retardation, and ataxia. Patient 
11 was presented with hepatosplenomegaly, hypotonia, 
and delayed developmental milestone by the age of 
2 years, with an early infantile onset of disease. The 
latter two frameshift mutations were not reported before 
in any populations rather than Egyptians. Two previously 
reported that Egyptian patients were described with the 
early infantile onset of disease [31]. Among cases with 
a late infantile-onset, we identified the novel missense 
variation p.Ser1169Arg in patient 4, her parents were 
both heterozygous carriers and showed normal 
phenotypes. The patient was suffering from 
hepatosplenomegaly, hypotonia, delayed 
developmental milestones, and psychomotor 
retardation that appeared after 2 years of age. The 
mutation p.Ser1169Arg is located in the cytoplasmic 
loop L between the 11thand 12th transmembrane 
domains. Functional effect prediction programs 
confirmed the possible pathogenesis of this novel 
variant. Moreover, it is found to be located within 
conserved regions when multiple alignment analysis 
was applied in eightdifferent species. Within the same 
region, p.Cys1168Tyr mutation was previously detected 
in a patient with the late infantile onset of disease, 
where immunoblotting of the mutated NPC1 protein 
showed a diminished amount of the protein [35]. This 
confirms the essential role of this region within the 
cytoplasmic loop L for the protein activity process. On 
the other hand, these predictions were confirmed by 
project HOPE, which illustrated the difference in size, 
charge, and hydrophobicity value between the wild 
residue serine and mutant arginine. The exchange of 
the buried neutral serine residue with larger positively 
charged arginine could abolish the core structure of the 
domain and affect protein binding. In addition, loss of 
hydrophobic interaction between the protein core and 
membrane lipids may be developed due to the less 
hydrophobic mutant residue arginine, which affects 
protein function. Another novel missense variant 
p.Ser1197Phe was observed in a homozygous state in 
three different patients (3, 7, and 13). Although, they 
were not relatives; the three patients were from the 
same village. Sequencing of parents showed the 
heterozygous status of the variant. Patients 7 and 
13had a late-infantile onset of disease and showed 
nearly similar manifestations. Splenomegaly was the 
main systemic feature, while neurological manifestations 
began after 4 years of age and included loss of speech 
progression, unsteady gait, and hypotonia in addition to 
VSGP. Concerning patient3, no systemic signs could 
be observed; she showed the juvenile form of the 
disease. Although three latter patients share the same 
variantp. Ser1197Phe, patient 3 showed different 
disease onset and clinical manifestations which 
highlight the extreme phenotypic heterogeneity of the 
disease. Despite considerable advances in biochemical 
andgenetic understanding of the disease, the cause of 
extensivephenotypic variability in NPC remains 
unclear [29]. The detected variant Ser1197phe is 
located within the12th transmembrane domain in a 
highly conserved region was confirmed by multiple 
alignment analysis. Functional effect prediction 
programs such asSIFT, PolyPhen2, 
andMutationTasterpredicted splice site alteration and 
possible pathogenicity after this novel variant. According 
to project HOPE, phenylalanine residue is larger and 
more hydrophobic than serine residue which may affect 
the protein contact with the lipid-membrane. In addition, 
in wild protein, the buried serine residue forms a 
hydrogen bond with glutamine at position 707, while in 
the mutant phenylalanine residue; loss of hydrogen 
bonds in the protein core is acquired dueto the difference 
in size and hydrophobicity of phenylalanine, leading to 
disruption of the protein correct folding.
Finally, mutation p.Gly910Ser was observed in 
the heterozygous state in patient 5 (6 months of age) 
who only suffered from hepatosplenomegaly while 
neurological manifestations havenot yet manifested on 
clinical evaluation, the same mutation was also reported 
in the heterozygous state coupled with p.Cys516Tyr 
mutation in a newborn infant with acute liver failure to 
parents of mixed Armenian and Turkish descent [37]. It 
was also observed in a patient with a juvenile form of 
the disease in the heterozygous state with p.Pro474Leu 
missense mutation in a previous Italian study [17]. Here, 
we could not detect the other heterozygous variant 
suggesting that patient may have another variant either 
in a more proximal portion of the NPC1or in NPC2.
Conclusion
Our study as one of the limited molecular 
studies on NPC1 gene of NPC Egyptian patients was 
able to investigate certain clinical, biochemical, and 
molecular characteristics in patients. It provides valuable 
information to enhance the recognition of some variations 
associated with NPC disease in Egyptians. The novel 
NPC1 variants p.Ser1169Arg and p.Ser1197Phe were 
mostly correlated with the late-infantile onset of the 
disease. Distribution of detected mutations revealed 
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that the two studied amino acid residues (855–1098 and 
1038–1253) could be considered as potentialhot spot 
regions in NPC1 Egyptian patients. Although NPC was 
variably distributed all over Egypt, a recurrent mutation 
within the same village illustrates the harmful impact of 
consanguineous marriage which would extend further 
from the unit of the family. Finally, the use of in silico 
bioinformatics tools for analysis of the pathogenicity of 
novel variants isa helpful, time-saving, and relatively 
accurate test. However, functional analysis of protein 
would be of great importance, especially in studies 
examining the disease pathogenesis and pathway.
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Figure S1: The revealed  reported mutations of NPC1 (a) represents the homozygous  nonsense mutation p.Arg958* detected  in patient 9; (b) 
shows the homozygous frameshift  mutation  p.Cys1011* detected in patient 10; (c) shows the heterozygous missense mutation p.Gly910Ser 
revealed in patient 5; (d) represents the homozygous frameshift mutation p.Arg927Gfs*38 observed in patient 11. The upper chromatogram in 
each frame represents the variant sequence; the lower one shows the reference sequence
a b
c d
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Figure S2: NPC1 protein topology and distribuition of the two novel missense variants (p.Ser1169Arg) and (p.Ser1197Phe). The 13 
transmembrane domains of NPC1 are represented in the middle; cytosolic domains are shown at the bottom part, and luminal domains are 
shown at the upper part of the figure. Novel sequence alterations are indicated at their positions
Figure S3: Cross-species conservation of the NPC1 protein 
sequence in relation to the two novel variants, (a) p.Ser1197Phe and 
(b) p.Ser1169Arg 
a
b
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Table S2: Biochemical analysis of 15 studied NPC patients
Patient no. Chitotriosidase µmol/l/h
Reference level (4–80 µmol/L/h)
Sphingomyelinase nmol/g.prot/h
Reference level (6–47 µl/g.prot/h/g.prot/h)
β-glucocerebrosidase µmol/g.prot/h
Reference level  (1–5 µmol/g/h)
1 101.3 13.4 1
2 88 23.4 1.5
3 107 11 1.2
4 282 30 4.7
5 195 25 3.2
6 171 7.3 2.6
7 159 8.7 2.5
8 242 7 3.5
9 380 14 2.5
10 195 25 3.2
11 615 17 1.3
12 329 7.3 2.8
13 188 1.7 1.8
14 215 13.7 5
15 692 9 1.5
no: Number.
Table S1: Primer sequences used to amplify NPC1 exons 
(17–25)
Exon No. Sequence Fragment size
17F F: 5_-CCTGTACTCCCTATTAGCCTGTCAT-3_ 322
17R R: 5_-ACTTGCTTGAAACACCTACGTGCATG-3
18F F:5_-TGCTTAGTTACTATCAGAGTGTTCAC-3_ 291
18R R:5_-CCTCCTCCGCTGCTTCTGAAGTA-3_
19F F:5_-CTGTGGAGCAGGTCAGTAACCCT-3_ 245
19R R:5_-GTATAAACTGAGGCACGATGCAAATG-3_
20F F: 5_-CTTCTAACAGTCCTCCCTGCA-3_ 247
20R R: 5_-CTGTCTTAGCCCAGTCCTCTC-3_
21F F: 5_-TGCTTAGCCTCAAGTGCTCAGAT-3_ 337
21R R: 5_-ACCCAGTGTAGGCCCTTTGCTG-3_
22F F: 5_-GCGAGCTTTAATGAGGCCTCC-3_ 295
22R R: 5_-GACAAACTGAGACTGTATGAGGA-3_
23F F: 5_-CAGGGTGCCCTGGGTAATTAGCA-3_ 292
23R R: 5_-GATCCAGACTCTTCAGTCACTGAG-3_
24F F: 5_-TTCAATTACAGGTTGGTAAAAGTGGTT-3_ 297
24R R: 5_-CTTGAAAAGAATGCCTCAGGATAGA-3_
25F F: 5_-TTCCAAAGTGGGATTACAGGCGTG-3_ 221
25R R: 5_-GACCGACCCTTAGACACAGTTCAG-3_
